EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature

Zenia Elavia, Victoria Jimenez, Roxanne Lockhart, Allison Muha, Mohamed Kazamel

Medicine International · 03.12.2024 · 5 (1)

DOI: 10.3892/mi.2024.210 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Medicine International, online erschienen am 03.12.2024. Verfasst von Zenia Elavia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Alabama, Birmingham, AL 35294, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

cemiplimabimmune checkpoint inhibitorsimmune-related adverse eventsintravenous immunoglobulinmyasthenia gravismyositisnivolumab

Autor:innen und Institutionen

  • Department of Neurology, University of Alabama, Birmingham, AL 35294, USA.

Zitieren

APA

Elavia, Z., Jimenez, V., Lockhart, R., Muha, A., & Kazamel, M. (2024). Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature. Medicine International, 5(1). https://doi.org/10.3892/mi.2024.210

Vancouver

Elavia Z, Jimenez V, Lockhart R, Muha A, Kazamel M. Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature. Medicine International. 2024;5(1). doi:10.3892/mi.2024.210

BibTeX
@article{Elavia2024,
  author = {Elavia, Zenia and Jimenez, Victoria and Lockhart, Roxanne and Muha, Allison and Kazamel, Mohamed},
  title = {Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature},
  journal = {Medicine International},
  year = {2024},
  volume = {5},
  number = {1},
  doi = {10.3892/mi.2024.210}
}
Kostenlos starten →